COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC)
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved..
Coronavirus disease 2019 (COVID-19) causes a wide range of symptoms, including several unexpected symptoms such as loss of taste, skin changes, and eye problems. We recently observed patients with documented COVID-19 develop de novo severe genitourinary symptoms, most notably urinary frequency of ≥ 13 episodes/24 h and nocturia ≥ 4 episodes/night. We call these associated urinary symptoms COVID-19 associate cystitis (CAC). COVID-19 severity is associated with inflammation. We collected urine samples from COVID-19 patients, including patients with CAC, and found elevation of proinflammatory cytokines also in the urine. It has been previously shown that patients with urinary incontinence and ulcerative interstitial cystitis/bladder pain syndrome have elevated urinary inflammatory cytokines compared to normal controls. We therefore hypothesize that CAC, with presentation of de novo severe urinary symptoms, can occur in COVID-19 and is caused by increased inflammatory cytokines that are released into the urine and/or expressed in the bladder. The most important implications of our hypothesis are: 1) Physician caring for COVID-19 patients should be aware of COVID-19 associate cystitis (CAC); 2) De novo urinary symptoms should be included in the symptom complex associated with COVID-19; and 3) COVID-19 inflammation may result in bladder dysfunction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:145 |
|---|---|
| Enthalten in: |
Medical hypotheses - 145(2020) vom: 01. Dez., Seite 110375 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lamb, Laura E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bladder |
|---|
| Anmerkungen: |
Date Completed 04.01.2021 Date Revised 12.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mehy.2020.110375 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317810952 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317810952 | ||
| 003 | DE-627 | ||
| 005 | 20231225164039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mehy.2020.110375 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1059.xml |
| 035 | |a (DE-627)NLM317810952 | ||
| 035 | |a (NLM)33213997 | ||
| 035 | |a (PII)S0306-9877(20)33266-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lamb, Laura E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2021 | ||
| 500 | |a Date Revised 12.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) causes a wide range of symptoms, including several unexpected symptoms such as loss of taste, skin changes, and eye problems. We recently observed patients with documented COVID-19 develop de novo severe genitourinary symptoms, most notably urinary frequency of ≥ 13 episodes/24 h and nocturia ≥ 4 episodes/night. We call these associated urinary symptoms COVID-19 associate cystitis (CAC). COVID-19 severity is associated with inflammation. We collected urine samples from COVID-19 patients, including patients with CAC, and found elevation of proinflammatory cytokines also in the urine. It has been previously shown that patients with urinary incontinence and ulcerative interstitial cystitis/bladder pain syndrome have elevated urinary inflammatory cytokines compared to normal controls. We therefore hypothesize that CAC, with presentation of de novo severe urinary symptoms, can occur in COVID-19 and is caused by increased inflammatory cytokines that are released into the urine and/or expressed in the bladder. The most important implications of our hypothesis are: 1) Physician caring for COVID-19 patients should be aware of COVID-19 associate cystitis (CAC); 2) De novo urinary symptoms should be included in the symptom complex associated with COVID-19; and 3) COVID-19 inflammation may result in bladder dysfunction | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bladder | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical symptoms | |
| 650 | 4 | |a Cytokine | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Nocturia | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Dhar, Nivedita |e verfasserin |4 aut | |
| 700 | 1 | |a Timar, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Wills, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Dhar, Sorabh |e verfasserin |4 aut | |
| 700 | 1 | |a Chancellor, Michael B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical hypotheses |d 1983 |g 145(2020) vom: 01. Dez., Seite 110375 |w (DE-627)NLM00007487X |x 1532-2777 |7 nnns |
| 773 | 1 | 8 | |g volume:145 |g year:2020 |g day:01 |g month:12 |g pages:110375 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mehy.2020.110375 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 145 |j 2020 |b 01 |c 12 |h 110375 | ||